picromycin and amrubicin

The toxic effects of combined cisplatin/docetaxel therapy cycles on erythroid and granulocytic hematopoietic lineages as well as their intercycle recovery were examined in patients with stage III-IV non-small-cell lung carcinoma. Responsiveness of the blood system to this therapy remained at a high level. Combined therapy pronouncedly activated the key elements of the erythroid and granulocytic hematopoietic lineages leading to accumulation of immature and mature myelokaryocytes in the bone marrow, enlargement of the medullary pool of mature neutrophils, and increase in the count of medullary erythroid and granulocytic precursor cells under conditions of their accelerated maturation.

Topics: Anthracyclines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cisplatin; Disaccharides; Docetaxel; Doxorubicin; Erythropoiesis; Granulocytes; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Macrolides; Nitrosourea Compounds; Organoplatinum Compounds; Taxoids